CD3 stimulants(T cell surface glycoprotein CD3 stimulants), GPRC5D inhibitors(G-protein coupled receptor family C group 5member D inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]

Active Indication

Refractory Multiple MyelomaRelapse multiple myelomaMultiple Myeloma+ [6]

Inactive Indication-

Originator Organization

Janssen Pharmaceuticals, Inc.

Active Organization

Janssen Research & Development LLC

Johnson & Johnson (China) Investment Ltd.Janssen-Cilag Pty Ltd.

+ [9]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (09 Aug 2023),

Multiple Myeloma

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan), Orphan Drug (South Korea), Conditional marketing approval (European Union), Conditional marketing approval (China)

Structure/Sequence

Sequence Code 10086313H

Source: *****

Sequence Code 10086327L

Source: *****

Sequence Code 453116282H

Source: *****

Sequence Code 525754800L

Source: *****

Clinical Trials associated with Talquetamab

NCT07474961

/ Not yet recruitingPhase 4IIT

A Multicentre, Adaptive, Randomised, Multidomain, Platform Trial for Dose Optimization in the Treatment of Adult Patients With Haematological Diseases (BLOOD-dose): Core Protocol

BLOOD-dose is a multicentre, adaptive, randomized, multidomain platform trial designed to optimize treatment dosing strategies in adult patients with haematological diseases.
The BLOOD-dose core protocol outlines the overall clinical trial design that applies to all included interventions, while domain-specific appendices (DSA) detail the unique characteristics of each domain and specify domain-specific interventions.
New domains will be incorporated over time to address distinct dose-optimization research questions across different haematological conditions and interventions.

Start Date01 Mar 2027

Sponsor / Collaborator

Rigshospitalet

NCT07029776

/ Not yet recruitingPhase 2

A Phase 2 Study Exploring the Use of Bispecific Antibodies to Improve Progression Free Survival in Patients With High-Risk Newly Diagnosed Multiple Myeloma (MMulti-Immune HR)

The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
The treatment on this study will consist of Induction chemotherapy and stem cell collection, Immunotherapy 1 chemotherapy and Immunotherapy 2 chemotherapy. For participants whose testing show they are Minimal Residual Disease (MRD) positive (still have myeloma cells present in the bone marrow testing), a Melphalan-based stem cell transplant will be performed. For participants whose testing show they are MRD negative, the stem cell transplant will not be performed. All participants will go on to receive Immunotherapy 3 chemotherapy, Immunotherapy 4 chemotherapy, and Maintenance therapy.

Start Date01 Mar 2027

Sponsor / Collaborator

University of Arkansas Fort Smith

[+1]

NCT07720843

/ Not yet recruitingPhase 1IIT

TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)

This is a Phase 1, open-label dose escalation study evaluating the safety and clinical efficacy of Talquetamab in combination with Belantamab mafodotin for a time-limited interval followed by Belantamab mafodotin and Pomalidomide maintenance.
The study will enroll subjects with Multiple Myeloma that have previously been treated with at least one prior line of therapy and have been treated with IMiDs, proteasome inhibitors, and anti-CD38 therapies either in combination or as single agent and are relapsed or are refractory to, or intolerant of, established therapies with clinical benefit in Multiple Myeloma.
Talquetamab will be administered with step up dosing on day 1, 3, 5 with or without day 7 pending target dose (TD1) of Talquetamab (Tal) in dose level. Two weeks after TD1, patients will enroll on C1D1 of Tal (TD2) with Belantamab (Bela). Tal will subsequently be dosed every two weeks. Bela will be administered every 8 weeks on D1 of odd numbered cycles or until resolution of any ocular toxicities to grade 1 or better. After 6 cycles of induction, patients may transition to Bela/Pom maintenance.

Start Date01 Sep 2026

Sponsor / Collaborator

Montefiore Medical Center

[+1]

100 Clinical Results associated with Talquetamab

100 Translational Medicine associated with Talquetamab

100 Patents (Medical) associated with Talquetamab

157

Literatures (Medical) associated with Talquetamab

31 Dec 2026·Hematology

Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experience

Article

Author: Campagna, Michela ; Qiu, Lugui ; Jin, Jie ; Zhang, Hong ; Gai, Xue ; Renaud, Thomas ; Xu, Qianqian ; Cai, Zhen ; Heuck, Christoph ; Fu, Chengcheng ; Zhu, Dian ; Masterson, Tara J. ; Lau, Bonnie W. ; Jing, Hongmei ; Li, Liang ; An, Gang ; Luo, Xinchao ; Liu, Rui ; Xia, Zhongjun ; He, Pengcheng

OBJECTIVES:

Talquetamab (G-protein-coupled receptor class C group 5 member D [GPRC5D] × CD3 bispecific antibody) demonstrated antitumor activity in relapsed/recurrent multiple myeloma (RRMM) in the phase I/II MonumenTAL-1 study. We report the safety profile of talquetamab in Chinese patients from MonumenTAL-1, focusing on GPRC5D-associated on-target/off-tumor adverse events (AEs).

METHODS:

Adult Chinese patients with heavily pretreated RRMM and measurable disease received subcutaneous talquetamab 0.4 mg/kg once weekly (QW) or 0.8 mg/kg biweekly (Q2W). Incidence, time to onset, duration, and recovery status of GPRC5D-associated AEs were reported. Data cutoffs: 29 February 2024 (QW cohort); 26 August 2024 (Q2W cohort).

RESULTS:

A total of 41 adult Chinese patients were included in this study (QW cohort, n = 29; Q2W cohort n = 12). Median treatment duration was 7.7 months (QW cohort) and 7.1 months (Q2W cohort); median follow-up was 16.3 and 13.9 months, respectively. GPRC5D on-target/off-tumor AEs, predominantly grade 1-2 (one grade 3 non-rash skin toxicity; QW cohort), were most commonly oral AEs (dysgeusia, dry mouth), skin AEs (rash, non-rash skin toxicity), and nail disorders; 50%-100% resolved by data cutoff. AEs were managed with supportive therapies. Talquetamab dose modification was needed in one case (grade 2 weight decrease).

DISCUSSION:

The generally mild GPRC5D-associated AEs were well tolerated and consistent with the known safety profile of talquetamab. Supportive management of these AEs without need for dose modification enabled prolonged treatment.

CONCLUSIONS:

Education of patients with RRMM on potential GPRC5D-associated AEs before starting treatment, and timely management upon experience, may ensure optimum exposure and thus maximum benefit with talquetamab.

31 Dec 2026·JOURNAL OF MEDICAL ECONOMICS

Costs per responder for patients with relapsed or refractory multiple myeloma treated with Talquetamab compared with usual care

Article

Author: Mu, Fan ; Patel, Neel ; Yang, Chelsey ; Jiao, Tianze ; Liu, Yi-Hsuan ; Grajales-Cruz, Ariel F. ; Lee, Hans C. ; Zhang, Xinke ; Wang, Jiamin ; Goble, Joseph

AIMS:

To evaluate costs per responder for patients with triple-class exposed (TCE) relapsed or refractory multiple myeloma (RRMM) receiving talquetamab (Tal) on weekly (QW) and biweekly (Q2W) dosing schedules, compared with usual care from a United States commercial payer's perspective.

METHODS:

A cost per responder model was developed over a 6-month time horizon, incorporating pre-progression and post-progression costs. For Tal QW and Tal Q2W, pre-progression costs included costs of drug acquisition, inpatient step-up doses (hospitalization, pre-medication, and tocilizumab), outpatient visits, and monitoring. Pre-progression costs for usual care were estimated based on a weighted average of the 10 most used regimens in a real-world LocoMMotion/MoMMent study, including costs of acquisition, administration, co-medication, and monitoring. Post-progression costs included subsequent treatment for a subset of patients and terminal care costs prior to death. All costs were reported in 2025 United States Dollars. Clinical data of overall response rate (ORR), progression-free survival, and overall survival were obtained from an indirect treatment comparison using MonumenTAL-1 (September 2024 data cut) and LocoMMotion/MoMMent (October 2022 and August 2023 data cuts) as data sources. Deterministic sensitivity analyses and scenario analyses were conducted to assess the robustness of model results.

RESULTS:

Over the 6-month period, the total cost of care was $179,556 for usual care, $295,993 for Tal QW, and $315,135 for Tal Q2W. Despite higher costs, Tal demonstrated superior ORR, resulting in lower cost per responder: $575,962 for usual care, $405,470 for Tal QW, and $443,165 for Tal Q2W, representing a 23-30% reduction in cost per responder with Tal. Sensitivity and scenario analyses showed consistent findings.

CONCLUSION:

Although Tal QW and Q2W are associated with higher total per-patient costs compared with usual care, they offer improved clinical effectiveness, resulting in lower cost per responder. These findings suggest greater economic value for Tal in the treatment of TCE RRMM.

01 Oct 2026·EUROPEAN JOURNAL OF HAEMATOLOGY

Condensed vs. Standard Step‐Up Dosing Schedule of Talquetamab in Relapsed/Refractory Multiple Myeloma

Article

Author: Khouri, Jack ; Kissam, Jonathan ; Hansen, Doris K. ; Gonzalez, Rebecca ; Rudoni, Joslyn ; Dominick, Anthony ; Mahmoudjafari, Zahra ; Davis, James A. ; Sborov, Douglas W. ; Rice, Mikhaila ; Granger, Katelynn ; Warrick, Matthew ; Grajales‐Cruz, Ariel ; Julian, Kelley ; Elsey, Grace ; Atrash, Shebli ; Snyder, Jordan ; McElwee, Jessica ; Vince, Megan ; Nachar, Victoria R. ; Ahmed, Iman ; Moore, Donald C. ; Bryan, Baylee ; Cahoon, Christopher ; Pianko, Matthew

ABSTRACT:

Objective:

To compare the incidence and severity of cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) between two different step‐up dosing (SUD) schedules with talquetamab, the standard SUD schedule of Days 1, 4, 7, and 10 and a condensed SUD schedule of Days 1, 3, 5, and 7.

Methods:

We conducted a multicenter retrospective study across seven academic medical centers in the United States and included patients who received talquetamab for the treatment of relapsed/refractory multiple myeloma. The incidence and grade of severity of CRS and ICANS were compared between patients receiving the standard SUD schedule and the condensed SUD schedule.

Results:

A total of 144 patients were included in our analysis; 33 received the standard SUD schedule and 111 received the condensed SUD schedule. The incidence of CRS (76% vs. 56%; p = 0.101) and ICANS (9% vs. 16%; p = 0.41) was similar between the standard and condensed SUD cohorts. There was no significant difference in the severity of CRS and ICANS between both cohorts.

Conclusion:

Shortening the interval between talquetamab SUDs appears feasible and well‐tolerated in routine clinical practice.

181

News (Medical) associated with Talquetamab

13 Oct 2026

·www.biospace.com

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%* 2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint Significant innovation including the market authorization of OTTAVA as the world’s first table-integrated soft tissue robotic system, approval of IMAAVY in warm autoimmune hemolytic anemia (wAIHA), and priority review for RYBREVANT FASPRO for advanced head and neck cancer NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026. “Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to reporting positive Phase 3 results in multiple myeloma. This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.” Overall financial results Q3 ($ in Millions, except EPS) 2026 2025 % Change Reported Sales $25,399 $23,993 5.9% Net Earnings $210 $5,152 (95.9)% EPS (diluted) $0.09 $2.12 (95.8)% Q3 Non-GAAP* ($ in Millions, except EPS) 2026 2025 % Change Operational Sales 1,2 6.0% Adjusted Operational Sales 1,3 6.1% Adjusted Net Earnings 1,4 $6,339 $6,801 (6.8)% Adjusted EPS (diluted) 1,4 $2.59 $2.80 (7.5)% Free Cash Flow 5,6 ~$15,100 $14,226 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency 4 Excludes intangible amortization expense and special items 5 Non-GAAP financial measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings. 6 Third-quarter YTD 2026 is estimated as of October 13, 2026 Note: values may have been rounded Regional sales results Q3 % Change ($ in Millions) 2026 2025 Reported Operational 1,2 Currency Adjusted Operational 1,3 U.S. $14,959 $13,708 9.1% 9.1 - 9.1 International 10,440 10,285 1.5 1.8 (0.3) 1.9 Worldwide $25,399 $23,993 5.9% 6.0 (0.1) 6.1 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Segment sales results Q3 % Change ($ in Millions) 2026 2025 Reported Operational 1,2 Currency Adjusted Operational 1,3 Innovative Medicine $16,757 $15,563 7.7% 7.9 (0.2) 8.0 MedTech 8,642 8,430 2.5 2.5 0.0 2.5 Worldwide $25,399 $23,993 5.9% 6.0 (0.1) 6.1 1 Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 2 Excludes the impact of translational currency 3 Excludes the net impact of acquisitions and divestitures and translational currency Note: values may have been rounded Third-Quarter 2026 segment commentary: Operational sales* reflected below excludes the impact of translational currency. Innovative Medicine Innovative Medicine worldwide operational sales grew 7.9%*, with divestitures negatively impacting growth by 10 basis points. Growth was primarily driven by TREMFYA and new products within Other in Immunology, DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE, and ERLEADA in Oncology, and SPRAVATO and CAPLYTA in Neuroscience. Growth was partially offset by STELARA (an approximate 690 basis points impact), SIMPONI/SIMPONI ARIA, and REMICADE in Immunology, as well as OPSUMIT/OPSYNVI in Pulmonary Hypertension, and IMBRUVICA in Oncology. MedTech MedTech worldwide operational sales grew 2.5%*. Growth was primarily driven by electrophysiology products and Shockwave in Cardiovascular, contact lenses in Vision, as well as trauma in Orthopaedics. Full-year 2026 guidance: Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP. ($ in Billions, except EPS) October 2026 July 29, 2026 Adjusted Operational Sales 1,2 Change vs. Prior Year / Mid-point 6.4% – 6.8% / 6.6% 6.2% – 6.8% / 6.5% Operational Sales 2 / Mid-point Change vs. Prior Year / Mid-point $100.5B – $100.9B /$100.7B 6.7% – 7.1% / 6.9% $100.3B – $100.9B / $100.6B 6.5% – 7.1% / 6.8% Estimated Reported Sales 3 / Mid-point Change vs. Prior Year / Mid-point $101.0B – $101.4B / $101.2B 7.2% – 7.6% / 7.4% $100.8B – $101.4B / $101.1B 7.0% – 7.6% / 7.3% Adjusted Operational EPS (Diluted) 2,4 / Mid-point Change vs. Prior Year / Mid-point $10.95 – $11.05 / $11.00 1.5% – 2.4% / 2.0% $10.86 – $11.01 / $10.94 0.7% – 2.1% / 1.4% Adjusted EPS (Diluted) 3,4 / Mid-point Change vs. Prior Year / Mid-point $11.05 – $11.15 / $11.10 2.4% – 3.3% / 2.9% $10.96 – $11.11 / $11.04 1.6% – 3.0% / 2.3% 1 Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures 2 Non-GAAP financial measure; excludes the impact of translational currency 3 Calculated using Euro Average Rate: October 2026 = $1.15 and July 2026 = $1.15 (Illustrative purposes only) 4 Non-GAAP financial measure; excludes intangible amortization expense and special items Note: percentages may have been rounded Other modeling considerations will be provided on the webcast. Notable announcements in the quarter: The information contained in this section should be read together with Johnson & Johnson’s other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at , or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company’s website at Investor News , as well as Innovative Medicine Newsroom , MedTech News & Events , and . Regulatory Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses 1 Press Release FDA approves IMAAVY ® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients Press Release Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer Press Release Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System Press Release Johnson & Johnson Announces MONARCH™ QUEST 3, Advancing the Latest in Robotically-Assisted Bronchoscopy Press Release Data Releases New Johnson & Johnson ICOTYDE ® (icotrokinra) long-term data demonstrate robust 2- year results in the treatment of adults and adolescents with plaque psoriasis 1 Press Release Johnson & Johnson announces new ICOTYDE™ (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy 1 Press Release Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY ® (nipocalimab-aahu) in generalized myasthenia gravis (gMG) Press Release Johnson & Johnson announces TREMFYA ® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study Press Release Single infusion of CARVYKTI ® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma Press Release New model-based analysis further supports the potential of TECVAYLI ® (teclistamab-cqyv) plus DARZALEX FASPRO ® (daratumumab and hyaluronidase-hj) to redene long-term survival expectations in early line relapsed/refractory multiple myeloma Press Release CAPLYTA ® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study Press Release RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE ® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 Press Release Johnson & Johnson's RYBREVANT ® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer Press Release Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026 Press Release TECVAYLI ® + TALVEY ® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma Press Release Other New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause 1 Press Release Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September Press Release Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation Press Release Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset Press Release Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation Press Release 1 Subsequent to the quarter Webcast information: Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations . About Johnson & Johnson: At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . Non-GAAP financial measures: * “Operational sales growth” excluding the impact of translational currency, “adjusted operational sales growth” excluding the net impact of acquisitions and divestitures and translational currency, as well as “adjusted net earnings”, “adjusted diluted earnings per share” and “adjusted operational diluted earnings per share” excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results . Copies of the financial schedules accompanying this earnings release are available on the company’s website at quarterly results . These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today’s earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results . Note to investors concerning forward-looking statements: This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; and the Company's ability to successfully separate the Company's Orthopaedics business and realize the anticipated benefits from the planned separation. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , , investor.jnj.com , or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) THIRD QUARTER NINE MONTHS Percent Change Percent Change 2026 2025 Total Operations Currency 2026 2025 Total Operations Currency Sales to customers by segment of business Innovative Medicine U.S. $ 10,447 9,402 11.1 % 11.1 - $ 29,297 26,655 9.9 % 9.9 - International 6,310 6,161 2.4 3.0 (0.6 ) 19,270 17,983 7.2 3.6 3.6 16,757 15,563 7.7 7.9 (0.2 ) 48,567 44,638 8.8 7.4 1.4 MedTech U.S. 4,512 4,306 4.8 4.8 - 13,525 12,902 4.8 4.8 - International 4,130 4,124 0.1 0.1 0.0 12,679 12,089 4.9 2.2 2.7 8,642 8,430 2.5 2.5 0.0 26,204 24,991 4.9 3.5 1.4 U.S. 14,959 13,708 9.1 9.1 - 42,822 39,557 8.3 8.3 - International 10,440 10,285 1.5 1.8 (0.3 ) 31,949 30,072 6.2 3.0 3.2 Worldwide $ 25,399 23,993 5.9 % 6.0 (0.1 ) $ 74,771 69,629 7.4 % 6.0 1.4 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Johnson & Johnson and Subsidiaries Supplementary Sales Data (Unaudited; Dollars in Millions) THIRD QUARTER NINE MONTHS Percent Change Percent Change 2026 2025 Total Operational Currency 2026 2025 Total Operational Currency Sales to customers by geographic area U.S. $ 14,959 13,708 9.1 % 9.1 - $ 42,822 39,557 8.3 % 8.3 - Europe 5,405 5,440 (0.6 ) 1.0 (1.6 ) 16,979 15,937 6.5 2.3 4.2 Western Hemisphere excluding U.S. 1,385 1,231 12.5 8.0 4.5 3,987 3,604 10.6 4.5 6.1 Asia-Pacific, Africa 3,650 3,614 1.0 1.0 0.0 10,983 10,531 4.3 3.6 0.7 International 10,440 10,285 1.5 1.8 (0.3 ) 31,949 30,072 6.2 3.0 3.2 Worldwide $ 25,399 23,993 5.9 % 6.0 (0.1 ) $ 74,771 69,629 7.4 % 6.0 1.4 Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) THIRD QUARTER 2026 2025 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 25,399 100.0 $ 23,993 100.0 5.9 Cost of products sold 8,097 31.9 7,303 30.4 10.9 Gross Profit 17,302 68.1 16,690 69.6 3.7 Selling, marketing and administrative expenses 6,285 24.7 5,922 24.7 6.1 Research and development expense 4,652 18.3 3,672 15.3 26.7 In-process research and development impairments 339 1.4 - - Interest (income) expense, net 31 0.1 18 0.1 Other (income) expense, net 5,780 22.8 (478 ) (2.0 ) Restructuring 181 0.7 63 0.3 Earnings before provision for taxes on income 34 0.1 7,493 31.2 (99.5 ) (Benefit from)/Provision for taxes on income (176 ) (0.7 ) 2,341 9.7 (107.5 ) Net earnings $ 210 0.8 $ 5,152 21.5 (95.9 ) Net earnings per share (Diluted) $ 0.09 $ 2.12 (95.8 ) Average shares outstanding (Diluted) 2,448.6 2,428.6 Effective tax rate (517.6 ) % 31.2 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income $ 7,672 30.2 $ 8,436 35.2 (9.1 ) Net earnings $ 6,339 25.0 $ 6,801 28.3 (6.8 ) Net earnings per share (Diluted) $ 2.59 $ 2.80 (7.5 ) Effective tax rate 17.4 % 19.4 % (1) See Reconciliation of Non-GAAP Financial Measures. Johnson & Johnson and Subsidiaries Condensed Consolidated Statement of Earnings (Unaudited; in Millions Except Per Share Figures) NINE MONTHS 2026 2025 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 74,771 100.0 $ 69,629 100.0 7.4 Cost of products sold 24,254 32.4 22,288 32.0 8.8 Gross Profit 50,517 67.6 47,341 68.0 6.7 Selling, marketing and administrative expenses 18,751 25.1 16,923 24.3 10.8 Research and development expense 11,832 15.8 10,413 15.0 13.6 In-process research and development impairments 375 0.5 - - Interest (income) expense, net 136 0.2 (62 ) (0.1 ) Other (income) expense, net 6,405 8.6 (7,692 ) (11.1 ) Restructuring 247 0.3 144 0.2 Earnings before provision for taxes on income 12,771 17.1 27,615 39.7 (53.8 ) Provision for taxes on income 1,792 2.4 5,927 8.6 (69.8 ) Net earnings $ 10,979 14.7 $ 21,688 31.1 (49.4 ) Net earnings per share (Diluted) $ 4.49 $ 8.94 (49.8 ) Average shares outstanding (Diluted) 2,445.8 2,424.8 Effective tax rate 14.0 % 21.5 % Adjusted earnings before provision for taxes and net earnings (1) Earnings before provision for taxes on income $ 24,153 32.3 $ 24,635 35.4 (2.0 ) Net earnings $ 20,034 26.8 $ 20,206 29.0 (0.9 ) Net earnings per share (Diluted) $ 8.19 $ 8.33 (1.7 ) Effective tax rate 17.1 % 18.0 % (1) See Reconciliation of Non-GAAP Financial Measures. Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures Third Quarter Nine Months Ended (Dollars in Millions Except Per Share Data) 2026 2025 2026 2025 Net Earnings, after tax- as reported $210 $5,152 $10,979 $21,688 Pre-tax Adjustments Litigation related 5,519 15 6,116 (6,894 ) Intangible Asset Amortization expense 1,240 1,048 3,732 3,435 Restructuring related 1 195 168 533 302 Orthopaedics separation related 369 - 746 - Acquisition, integration and divestiture related (34 ) 97 142 475 (Gains)/losses on securities 10 (387 ) (262 ) (327 ) IPR&D impairments 339 - 375 - Other - 2 - 29 Tax Adjustments Tax impact on special item adjustments 2 (1,677 ) (168 ) (2,469 ) 826 Tax legislation and other tax related 168 874 142 672 Adjusted Net Earnings , after tax $6,339 $6,801 $20,034 $20,206 Average shares outstanding (Diluted) 2,448.6 2,428.6 2,445.8 2,424.8 Adjusted net earnings per share (Diluted) $2.59 $2.80 $8.19 $8.33 Operational adjusted net earnings per share (Diluted) $2.61 $8.04 Notes: 1 In the fiscal second quarter of 2026, the Company initiated a supply chain restructuring program primarily in the Innovative Medicine segment to exit certain manufacturing locations as part of its optimization efforts to streamline operations. The program is expected to be substantially completed by the end of fiscal year 2029 with estimated costs between $650 - $750 million, and include site and supplier exit costs, decommissioning and asset impairment costs. Restructuring expenses of $74 million in the fiscal third quarter of 2026 ($274 million Q3 2026 YTD), were primarily related to asset impairments and exit costs. In fiscal 2025, the Company initiated a restructuring program of its Surgery franchise within the MedTech segment to simplify and focus operations by exiting certain non-strategic product lines and optimize select sites across the network. Restructuring expenses of $80 million were recorded in the fiscal third quarter of 2026 ($194 million Q3 2026 YTD) and $128 million in the fiscal third quarter of 2025 ($157 million Q3 2025 YTD) primarily includes costs related to product exits. This program is expected to be substantially completed by the end of fiscal year 2026. In fiscal 2023, the Company initiated a restructuring program of its Orthopaedics franchise within the MedTech segment to streamline operations by exiting certain markets, product lines and distribution network arrangements. The restructuring expenses of $41 million in the fiscal third quarter of 2026 ($65 million Q3 2026 YTD) and $40 million in the fiscal third quarter of 2025 ($145 million Q3 2025 YTD) includes costs related to market and product exits. This program will be completed as of Q4 2026 at a total cost of approximately $1 billion. 2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Contacts Media contact: media-relations@its.jnj.com Investor contact: investor-relations@its.jnj.com Read full story here

Phase 3Executive ChangeDrug ApprovalFinancial StatementClinical Result

07 Oct 2026

·www.globenewswire.com

NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer

NeOnc’s encouraging brain-cancer survival findings join developments from Revolution Medicines, Moderna and Merck, Johnson & Johnson, and Genmab and AbbVie.DENVER, Oct. 07, 2026 (GLOBE NEWSWIRE) -- (www.247marketnews.com)-- For patients facing cancer, progress ultimately comes down to a deeply personal question: Can treatment give them more time? A series of developments reported during 2026 is providing new reasons for hope. From an approved treatment for advanced pancreatic cancer to personalized cancer immunotherapy and encouraging survival observations in recurrent brain cancer, publicly traded companies are advancing different approaches to some of medicine’s most difficult challenges. These developments span different levels of clinical evidence, from exploratory Phase 2 findings to randomized Phase 3 results and an FDA approval. SEC 24/7 Market News highlights five advances worth following as the year moves into its final quarter, beginning with NeOnc Technologies Holdings and its work in a particularly difficult treatment setting: aggressive brain cancer that has returned after previous therapy. NeOnc Technologies Holdings (NASDAQ: NTHI): Encouraging Survival Findings Where Better Options Are Urgently Needed NeOnc stands out in this group for the challenge it is confronting. Recurrent high-grade brain cancer remains an exceptionally difficult treatment setting. The National Cancer Institute notes that recurrent central nervous system tumors are rarely curable, underscoring the importance of developing additional treatment options. Cancer.gov On August 12, NeOnc reported that patients in its 24-patient Phase 2a study of intranasal NEO100 achieved a median overall survival of 26.09 months. Estimated survival was 60.9% at 12 months and 54.1% at 24 months. Importantly, survival was measured from the first treatment dose following recurrence, not from the original diagnosis. The study involved patients with recurrent or progressive Grade III and Grade IV IDH1-mutant glioma. SEC The treatment approach is also distinctive. NEO100 is administered intranasally by patients at home and is designed to reach the brain through pathways that bypass the blood-brain barrier, a major obstacle in brain-cancer drug delivery. NeOnc reported predominantly low-grade adverse events and no major toxicities in the cohort. SEC These findings represent an encouraging survival signal, not a randomized demonstration of improved survival. The study had no concurrent control group, and progression-free-survival findings varied by assessment method, reaching statistical significance against the historical benchmark under RANO 2.0 but not under the original protocol-specified criteria. NeOnc has outlined plans to discuss a registrational development pathway with the FDA. SEC For a disease setting where treatment options are limited, the combination of observed survival, reported tolerability and an at-home delivery approach makes NEO100 a development worth following as further clinical evaluation proceeds. Cancer.gov Revolution Medicines (NASDAQ): A Pancreatic-Cancer Advance That Has Already Reached Approval Revolution Medicines delivered one of the year’s clearest examples of clinical progress translating into an available treatment. On August 26, the FDA approved Rasonque, or daraxonrasib, a targeted therapy for metastatic pancreatic adenocarcinoma. Revolution Medicines In a randomized study involving 500 previously treated patients, median overall survival reached 13.2 months with Rasonque versus 6.7 months with standard chemotherapy. Unlike an uncontrolled survival observation, this result established a benefit against a treatment comparator within the same trial. U.S. Food and Drug Administration The approval is particularly meaningful in pancreatic cancer, where aggressive disease, late detection and historically limited treatment options have contributed to poor outcomes. It also provides a concrete example of what successful clinical development can accomplish: moving a promising approach from research into patient care. U.S. Food and Drug Administration Moderna (NASDAQ) and Merck (NYSE): Personalized Cancer Immunotherapy Reaches a Phase 3 Milestone Moderna and Merck reported a different kind of advance on August 19: positive Phase 3 results for intismeran autogene, an individualized mRNA-based cancer therapy, combined with Keytruda. The INTerpath-001 trial demonstrated statistically significant improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone in patients whose high-risk melanoma had been surgically removed. According to the companies, this was the first positive Phase 3 result for an individualized neoantigen therapy and an mRNA-based cancer treatment. Merck.com The approach is designed around the characteristics of an individual patient’s tumor. Its promise is not a universal vaccine against cancer, but a more personalized immune response to the disease. Overall-survival follow-up continues, while the companies plan to engage regulators regarding potential submissions. Merck.com Johnson & Johnson (NYSE): Dual-Target Immunotherapy Delivers Substantial Myeloma Results On July 23, Johnson & Johnson reported that combining Tecvayli and Talvey in the Phase 3 MonumenTAL-6 trial reduced the relative risk of disease progression or death by 89%, and the relative risk of death by 62%, compared with the study’s standard-treatment options. The trial involved patients with relapsed or refractory multiple myeloma who had received one to four prior treatment lines. The combination targets two different proteins associated with myeloma cells, BCMA and GPRC5D, directing immune activity against the disease through complementary targets. JNJ.com The investigational combination’s improvements in both disease control and overall survival support the potential to bring this dual-target approach earlier into treatment. The reported percentages describe relative reductions in risk, not percentages of patients cured. JNJ.com Genmab (NASDAQ) and AbbVie (NYSE): New Hope in First-Line Aggressive Lymphoma On October 5, Genmab and AbbVie announced that adding epcoritamab to the standard R-CHOP regimen reduced the relative risk of progression or death by 51% in the Phase 3 EPCORE DLBCL-2 trial. The reported result applied to newly diagnosed diffuse large B-cell lymphoma patients with International Prognostic Index scores of 2–5. Its importance lies in the possibility of improving treatment at the outset, rather than waiting until the disease returns. AbbVie News Center The combination remains investigational. The companies plan regulatory discussions and presentation of the findings at a future medical meeting, making this another development to follow beyond its initial announcement. AbbVie News Center Taken together, these developments offer reasons for optimism without suggesting that every clinical question has been answered. An approved therapy, positive randomized trials and an early survival signal occupy different positions along the development path. Their shared importance is the effort to improve outcomes where existing treatments remain insufficient. For NeOnc, the coming months also include a confirmed November 17, 2026, FDA End-of-Phase 1 meeting for its separate NEO212 program, covering proposed clinical-development plans and the evidence needed for a potential future marketing application. That meeting is distinct from NEO100’s development discussions and does not itself establish an agreed approval pathway. SEC The hopeful turn in 2026 is not that cancer has been solved. It is that several approaches are producing evidence worth advancing and, in some cases, treatments patients can already receive. For patients and families, the ultimate significance is not a company’s size or stock symbol. It is the possibility of more birthdays, more ordinary days, and more time together. About 24/7 Market News In today's fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you're an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory. PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor. Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures. CONTACT:24/7 Market NewsEditor@247mnn.com Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

Clinical ResultPhase 3Phase 2VaccineImmunotherapy

02 Oct 2026

·www.biopharmadive.com

Novartis wagers almost $8B on a Chinese biotech’s RNA drugs

China-based Abogen Biosciences has entered a deal with Novartis worth as much as $7.8 billion, giving the latter access to a drugmaking technology as well as an option for a next-generation T cell engager.The companies announced Friday that Novartis would pay Abogen $575 million up front to gain an option to license ABO2203, which Abogen describes as an mRNA-encoded biologic that targets CD3 and CD19, two proteins found on the surface of immune cells. Its drug provides the instructions for producing T cell engagers to cells, rather than traditional T cell engagers, which are usually developed in the lab and given to patients.Abogen presented early data in April from a study of ABO2203 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, showing it was well-tolerated in trial participants. Three patients experienced significant adverse events after receiving treatment, including drops in white blood cell counts and levels of proteins necessary for blood to clot. Those side effects were resolved over the course of the trial, however.The biotechs experimental programs represent an innovative approach that could complement existing therapeutic modalities by enabling in vivo production of these molecules, Fiona Marshall, head of Novartis biomedical research division, said in a statement.Abogen is part of a wave of biotechnology firms trying to develop ways to reset the immune system using T cell engagers. A handful of those drugs, such as Tecvayli and Talvey, have been approved to treat hematological cancers. But drugmakers have been interested in recent years in deploying those drugs against autoimmune conditions.Makers of T cell engagers and other dual-targeting antibodies have promoted such treatments as a safer alternative to cell therapies, which can prompt overreactions from the immune system. Theyre also costlier to manufacture.Other large drug developers that have bought into T cell engager technologies this year include Bristol Myers Squibb, Gilead Sciences and Vertex Pharmaceuticals. Those multispecific biologics have also been the center of at least a dozen licensing deals between U.S. or European drugmakers and Chinese developers, according to BioPharma Dive data.Abogen is eligible for as much as $7.2 billion in additional payments, contingent on hitting certain R&D and commercialization milestones. Novartis could also license other programs from them.The Swiss pharma has been under investor pressure after a series of experimental drugs failed in testing in September. Novartis paused a trialof its autoimmune CAR-T therapy after three patients died. A genetic medicine it was developing with Ionis Pharmaceuticals did not prove it could protect cardiovascular health. Another drug called del-desiran, acquired in Novartis purchase of Avidity Biosciences, failed a key clinical trial.Jefferies analyst Michael Leuchten wrote in a note to clients on Sept. 8 that those failures will likely raise questions again about Novartis due diligence and [business development] approach. '

AcquisitionClinical Result

100 Deals associated with Talquetamab

External Link

KEGG	Wiki	ATC	Drug Bank
D12180	-	-	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Refractory Multiple Myeloma	Japan	Janssen Pharmaceutical KK	24 Jun 2025
Relapse multiple myeloma	Japan	Janssen Pharmaceutical KK	24 Jun 2025
Multiple Myeloma	United States	Janssen Biotech, Inc.	09 Aug 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Residual Neoplasm	Phase 3	-	Johnson & Johnson	01 Sep 2026
Recurrent Multiple Myeloma	Phase 2	United States	Johnson & Johnson Pharmaceutical Research & Development LLC	17 Jul 2026
Recurrent Multiple Myeloma	Phase 2	United States	Janssen Research & Development LLC	17 Jul 2026
Peripheral Stem Cell Transplantation	Phase 2	United States	Janssen Scientific Affairs LLC	05 Jun 2025
Smoldering Multiple Myeloma	Phase 2	United States	Janssen Scientific Affairs LLC	04 Dec 2023
Extramedullary Disease in Multiple Myeloma	Phase 2	Spain	Janssen Pharmaceutica NV	21 Sep 2023
Hematologic Neoplasms	Phase 1	United States	Janssen Research & Development LLC	16 Dec 2017
Hematologic Neoplasms	Phase 1	Belgium	Janssen Research & Development LLC	16 Dec 2017
Hematologic Neoplasms	Phase 1	Netherlands	Janssen Research & Development LLC	16 Dec 2017
Hematologic Neoplasms	Phase 1	Spain	Janssen Research & Development LLC	16 Dec 2017

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05455320 (MonumenTAL-3, IMS2026)	Phase 3	Relapse multiple myeloma Second line	864	Talquetamab (Tal) + Daratumumab (D) + Pomalidomide (P)	xrgcahfcmx(unlgkkfxmi) = krsbfiihji pkrxdhguzi (nuzuibppko, 75.8 - 85.7) View more	Positive	23 Sep 2026
				Talquetamab (Tal) + Daratumumab (D)	xrgcahfcmx(unlgkkfxmi) = jkgzeoebyt pkrxdhguzi (nuzuibppko, 71.7 - 82.5) View more
IMS2026	Not Applicable	Plasma Cell Neoplasms	10	Talquetamab	znctaclbfh(peakrqrawl) = Taste/oral, skin, and nail changes occurred in 9/10, 6/10, and 6/10, respectively. Talquetmab-induced dizziness-ataxia syndrome occurred in 2/10. afnokjiwqk (kirdwnjgrx )	Positive	23 Sep 2026
IMS2026	Not Applicable	Multiple Myeloma	129	Talquetamab	wvlhubnltd(mkzmkiriii) = qxsmnipmkv qgususjmja (ecqgydimxp ) View more	Positive	23 Sep 2026
				Talquetamab (Renal Insufficiency)	jdakduuwdo(gmyureinau) = nibhmaeqed tlaawkyqry (mvmrewaapl ) View more
IMS2026	Not Applicable	Multiple Myeloma GPRC5D	220	Cilta-cel	cakiolydzt(uqgiyipfxp) = ewpzjsckgg noklvajiyu (djmefytfgr ) View more	Negative	23 Sep 2026
				Ide-cel	lxklnshfjn(vrkryokxxp) = ahhcxtbfcu kahzsjoeyr (taxhqgefgh ) View more
MonumenTAL-1 (IMS2026)	Phase 2	Relapse multiple myeloma	50	Talquetamab+Tocilizumab	hwusdrgzmf(uvkfasoama) = bozxhjyuho ffgwhniavc (kfjegtrjcd ) View more	Positive	23 Sep 2026
				Talquetamab+Tocilizumab (2 SUDs(0.06 mg/kg and 0.4 mg/kg))	hwusdrgzmf(uvkfasoama) = ofneliynyh ffgwhniavc (kfjegtrjcd ) View more
IMS2026	Not Applicable	Multiple Myeloma	176	Talquetamab	bvkbavypra(autnyxajfw) = fbacqwfvzz fgkobrbkxi (tohqkoysvz, 12.0 - NE) View more	Positive	23 Sep 2026
				Talquetamab (USPI criteria)	bvkbavypra(autnyxajfw) = dgryliwdhi fgkobrbkxi (tohqkoysvz, 10.8 - NE) View more
IMS2026	Not Applicable	Relapse multiple myeloma	126	Talquetamab	bbimwbcigi(gcrjbibavw) = xsfmuynsmu patuvioiqy (pdjgzbjjua ) View more	Positive	23 Sep 2026
NCT06500884 (TALisman, IMS2026)	Phase 2	Multiple Myeloma	58	Talquetamab	prcryrnnne(ymawmhtvgi) = bqotgpuldz awvjfhtobc (yvuygndhdi ) View more	Negative	23 Sep 2026
				Talquetamab+clonazepam	prcryrnnne(ymawmhtvgi) = cuvwojmvsz awvjfhtobc (yvuygndhdi ) View more
IMS2026	Not Applicable	Relapse multiple myeloma	9	Teclistamab (Tec) and/or Talquetamab (Tal)	dbwtpxhvtl(veaotnpvgt) = No CRS or major infections were observed, and one patient experienced grade 2 ICANS which resolved within 48 hours. gplykakuoq (xwrxwuabmn ) View more	Positive	23 Sep 2026
TARGET-LATAM (IMS2026)	Not Applicable	Relapse multiple myeloma	114	teclistamab or elranatamab (BCMA)	vzoefmnrld(ptocythdjv) = juarzphzzu qwvlhupote (ivpqwidmdc ) View more	Positive	23 Sep 2026
				talquetamab (GPRC5D)	vzoefmnrld(ptocythdjv) = rlzpdkvrzv qwvlhupote (ivpqwidmdc ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis